Prudential PLC vs Roivant Sciences Ltd. Common Shares — how do they compare? Prudential PLC trades at $24.03 (market cap $28.84B), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $24.72B). The key difference: Prudential PLC is the larger of the two by market cap, and Prudential PLC pays a 2.33% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prudential PLC for 119 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| PUK | ROIV | |
|---|---|---|
Market Cap | $28.84B | $24.72B |
Volume | 3,531,298 | 6,279,442 |
Sector | Financials | Health |
52-Week High | $33.61 | $41.81 |
52-Week Low | $23.54 | $16.04 |
Typical Hold Time | 119 Days | 0 Days |
Enterprise Value | $28.38B | $20.99B |
Dividend Yield | 2.33% | — |
Signals from Pluang's Aura AI — not financial advice
PUK trades at $23.54, down 4.31% today, amid bearish technical signals. The company shows strong fundamentals with revenue growth from $16.2B in 2024 to $27.4B in 2025 and net income of $4.0B. Valuation ratios appear attractive with P/E of 8.28 and P/S of 1.01. Recent news highlights strategic shifts including emerging-market exits and a $3B capital rotation plan. Analyst consensus is moderately bullish with 50% buy ratings.
The outlook balances solid profitability and growth against technical weakness and macroeconomic risks. Investment appeal lies in undervalued metrics and strategic refocusing, but near-term price pressure and execution risks on new initiatives warrant caution. The stock offers value for long-term investors if the company delivers on its five-year strategic targets.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →